{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:48:46Z","timestamp":1794973726556,"version":"4.9.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DOD CDMRP OR130302"],"award-info":[{"award-number":["DOD CDMRP OR130302"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NIH R01 CA224241"],"award-info":[{"award-number":["NIH R01 CA224241"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["2P30 CA068485-14"],"award-info":[{"award-number":["2P30 CA068485-14"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["2P30 CA068485-14"],"award-info":[{"award-number":["2P30 CA068485-14"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["NIH R01 EB019409"],"award-info":[{"award-number":["NIH R01 EB019409"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["NIH R21 AR078636"],"award-info":[{"award-number":["NIH R21 AR078636"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["NIH T32GM007347"],"award-info":[{"award-number":["NIH T32GM007347"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004472"],"award-info":[{"award-number":["BX004472"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004472"],"award-info":[{"award-number":["BX004472"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004151"],"award-info":[{"award-number":["BX004151"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004151"],"award-info":[{"award-number":["BX004151"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004472"],"award-info":[{"award-number":["BX004472"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004472"],"award-info":[{"award-number":["BX004472"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Osteoarthritis and rheumatoid arthritis are debilitating joint diseases marked by pain, inflammation and cartilage destruction. Current osteoarthritis treatments only relieve symptoms, while rheumatoid arthritis therapies can cause immune suppression and provide variable efficacy. Here we developed an optimized small interfering RNA targeting matrix metalloproteinase 13 for preferential delivery to arthritic joints. Chemical modifications in a stabilizing \u2018zipper\u2019 pattern improved RNA resistance to degradation, and two independent linkers with 18 ethylene glycol repeats connecting to tandem C18 lipids enhanced albumin binding and targeted delivery to inflamed joints following intravenous administration. In preclinical models of post-traumatic osteoarthritis and rheumatoid arthritis, a single intravenous injection of the albumin-binding small interfering RNA achieved long-term joint retention, sustained gene silencing and reduced matrix metalloproteinase 13 activity over 30\u2009days, resulting in decreased cartilage erosion and improved clinical outcomes, including reduced joint swelling and pressure sensitivity. This approach demonstrated superior efficacy over corticosteroids and small-molecule MMP inhibitors, highlighting the therapeutic promise of albumin \u2018hitchhiking\u2019 for targeted, systemic delivery of gene-silencing therapeutics to treat osteoarthritis and rheumatoid arthritis.<\/jats:p>","DOI":"10.1038\/s41551-025-01376-x","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:02:10Z","timestamp":1747371730000},"page":"1366-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["siRNA conjugate with high albumin affinity and degradation resistance for delivery and treatment of arthritis in mice and guinea pigs"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-4246","authenticated-orcid":false,"given":"Juan M.","family":"Colazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0099-4340","authenticated-orcid":false,"given":"Megan C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1935-0566","authenticated-orcid":false,"given":"Veeraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella N.","family":"Hoogenboezem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9171-8795","authenticated-orcid":false,"given":"Nina T.","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-5611","authenticated-orcid":false,"given":"Alexander G.","family":"Sorets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlisle R.","family":"DeJulius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4191","authenticated-orcid":false,"given":"Danielle L.","family":"Michell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Maerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacey C.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-1580","authenticated-orcid":false,"given":"Katherine N.","family":"Gibson-Corley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Hasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-5738","authenticated-orcid":false,"given":"Leslie J.","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3979-0620","authenticated-orcid":false,"given":"Craig L.","family":"Duvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.joca.2013.05.020","volume":"21","author":"RF Loeser","year":"2013","unstructured":"Loeser, R. F. Osteoarthritis year in review 2013: biology. Osteoarthr. Cartil. 21, 1436\u20131442 (2013).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.semarthrit.2018.10.001","volume":"48","author":"TR Gullo","year":"2019","unstructured":"Gullo, T. R. et al. Defining multiple joint osteoarthritis, its frequency and impact in a community-based cohort. Semin. Arthritis Rheum. 48, 950\u2013957 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205\u20132219 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00005-011-0116-3","volume":"59","author":"S Shiozawa","year":"2011","unstructured":"Shiozawa, S., Tsumiyama, K., Yoshida, K. & Hashiramoto, A. Pathogenesis of joint destruction in rheumatoid arthritis. Arch. Immunol. Ther. Exp. 59, 89\u201395 (2011).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1056\/NEJM199107113250203","volume":"325","author":"JD Bradley","year":"1991","unstructured":"Bradley, J. D., Brandt, K. D., Katz, B. P., Kalasinski, L. A. & Ryan, S. I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N. Engl. J. Med. 325, 87\u201391 (1991).","journal-title":"N. Engl. J. Med."},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"MC Hochberg","year":"2012","unstructured":"Hochberg, M. C. et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 64, 465\u2013474 (2012).","journal-title":"Arthritis Care Res."},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","volume":"22","author":"TE McAlindon","year":"2014","unstructured":"McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr. Cartil. 22, 363\u2013388 (2014).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR8","unstructured":"Benjamin, O., Goyal, A. & Lappin, S. L. Disease-Modifying Antirheumatic Drugs (DMARD) (StatPearls, 2022)."},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.freeradbiomed.2018.08.038","volume":"132","author":"JA Bolduc","year":"2019","unstructured":"Bolduc, J. A., Collins, J. A. & Loeser, R. F. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic. Biol. Med. 132, 73\u201382 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1177\/1535370217699534","volume":"242","author":"IC Young","year":"2017","unstructured":"Young, I. C. et al. A novel compressive stress-based osteoarthritis-like chondrocyte system. Exp. Biol. Med. 242, 1062\u20131071 (2017).","journal-title":"Exp. Biol. Med."},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/art.1780360512","volume":"36","author":"HE Jasin","year":"1993","unstructured":"Jasin, H. E., Noyori, K., Takagi, T. & Taurog, J. D. Characteristics of anti-type II collagen antibody binding to articular cartilage. Arthritis Rheum. 36, 651\u2013659 (1993).","journal-title":"Arthritis Rheum."},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1172\/JCI118357","volume":"96","author":"AP Hollander","year":"1995","unstructured":"Hollander, A. P. et al. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J. Clin. Invest. 96, 2859\u20132869 (1995).","journal-title":"J. Clin. Invest."},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.matbio.2014.08.007","volume":"39","author":"RF Loeser","year":"2014","unstructured":"Loeser, R. F. Integrins and chondrocyte\u2013matrix interactions in articular cartilage. Matrix Biol. 39, 11\u201316 (2014).","journal-title":"Matrix Biol."},{"key":"1376_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/ar2315","volume":"9","author":"P Krzeski","year":"2007","unstructured":"Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 9, R109 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/01.cad.0000176504.86551.5c","volume":"16","author":"JR Molina","year":"2005","unstructured":"Molina, J. R. et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 16, 997\u20131002 (2005).","journal-title":"Anticancer Drugs"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2174\/138945009789753264","volume":"10","author":"AL Clutterbuck","year":"2009","unstructured":"Clutterbuck, A. L., Asplin, K. E., Harris, P., Allaway, D. & Mobasheri, A. Targeting matrix metalloproteinases in inflammatory conditions. Curr. Drug Targets 10, 1245\u20131254 (2009).","journal-title":"Curr. Drug Targets"},{"key":"1376_CR17","doi-asserted-by":"publisher","first-page":"24091","DOI":"10.1074\/jbc.M114.583443","volume":"289","author":"JM Howes","year":"2014","unstructured":"Howes, J. M. et al. The recognition of collagen and triple-helical toolkit peptides by MMP-13: sequence specificity for binding and cleavage. J. Biol. Chem. 289, 24091\u201324101 (2014).","journal-title":"J. Biol. Chem."},{"key":"1376_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1947603511435273","volume":"3","author":"X Zhang","year":"2012","unstructured":"Zhang, X., Chen, C. T., Bhargava, M. & Torzilli, P. A. A comparative study of fibronectin cleavage by MMP-1, -3, -13, and -14. Cartilage 3, 267\u2013277 (2012).","journal-title":"Cartilage"},{"key":"1376_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/ar4133","volume":"15","author":"M Wang","year":"2013","unstructured":"Wang, M. et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res. Ther. 15, R5 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1376_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/138920108783497659","volume":"9","author":"H Takaishi","year":"2008","unstructured":"Takaishi, H., Kimura, T., Dalal, S., Okada, Y. & D\u2019Armiento, J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr. Pharm. Biotechnol. 9, 47\u201354 (2008).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1376_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/bs.pmbts.2017.04.003","volume":"148","author":"J Liu","year":"2017","unstructured":"Liu, J. & Khalil, R. A. Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog. Mol. Biol. Transl. Sci. 148, 355\u2013420 (2017).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"1376_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","volume":"9","author":"AV Kristen","year":"2019","unstructured":"Kristen, A. V. et al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manage. 9, 5\u201323 (2019).","journal-title":"Neurodegener. Dis. Manage."},{"key":"1376_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams, D. et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30, 1\u20139 (2023).","journal-title":"Amyloid"},{"key":"1376_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/s41551-021-00780-3","volume":"5","author":"SK Bedingfield","year":"2021","unstructured":"Bedingfield, S. K. et al. Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat. Biomed. Eng. 5, 1069\u20131083 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1376_CR25","doi-asserted-by":"publisher","first-page":"14475","DOI":"10.1021\/acsnano.1c04005","volume":"15","author":"SK Bedingfield","year":"2021","unstructured":"Bedingfield, S. K. et al. Top-down fabricated microplates for prolonged, intra-articular matrix metalloproteinase 13 siRNA nanocarrier delivery to reduce post-traumatic osteoarthritis. ACS Nano 15, 14475\u201314491 (2021).","journal-title":"ACS Nano"},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-023-01067-4","volume":"20","author":"CR DeJulius","year":"2024","unstructured":"DeJulius, C. R. et al. Engineering approaches for RNA-based and cell-based osteoarthritis therapies. Nat. Rev. Rheumatol. 20, 81\u2013100 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1376_CR27","doi-asserted-by":"crossref","unstructured":"Sleep, D., Cameron, J. & Evans, L. R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830, 5526\u20135534 (2013).","DOI":"10.1016\/j.bbagen.2013.04.023"},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"A132","DOI":"10.1016\/j.joca.2015.02.863","volume":"23","author":"MF Hsueh","year":"2015","unstructured":"Hsueh, M. F., Khabut, A., Kjellstrom, S., Onnerfjord, P. & Kraus, V. B. Cartilage permeability assessment based on proteomic analysis of plasma protein penetration. Osteoarthr. Cartil. 23, A132\u2013A133 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00300809","volume":"14","author":"M Mannik","year":"1994","unstructured":"Mannik, M. & Person, R. E. Deep penetration of antibodies into the articular cartilage of patients with rheumatoid arthritis. Rheumatol. Int. 14, 95\u2013102 (1994).","journal-title":"Rheumatol. Int."},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","volume":"170","author":"A Wunder","year":"2003","unstructured":"Wunder, A. et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 170, 4793\u20134801 (2003).","journal-title":"J. Immunol."},{"key":"1376_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-12-68","volume":"12","author":"M Liu","year":"2012","unstructured":"Liu, M. et al. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol. 12, 68 (2012).","journal-title":"BMC Biotechnol."},{"key":"1376_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73\u201389 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0031-6997(25)06849-8","volume":"33","author":"U Kragh-Hansen","year":"1981","unstructured":"Kragh-Hansen, U. Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev. 33, 17\u201353 (1981).","journal-title":"Pharmacol. Rev."},{"key":"1376_CR34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/1869","volume":"5","author":"S Curry","year":"1998","unstructured":"Curry, S., Mandelkow, H., Brick, P. & Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5, 827\u2013835 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"1376_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1517\/17425247.2010.498474","volume":"7","author":"E Neumann","year":"2010","unstructured":"Neumann, E. et al. Native albumin for targeted drug delivery. Expert Opin. Drug Deliv. 7, 915\u2013925 (2010).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1376_CR36","doi-asserted-by":"crossref","unstructured":"Carter, D. C. & Ho, J. X. Structure of serum albumin. Adv. Protein Chem. 45, 153\u2013203 (1994).","DOI":"10.1016\/S0065-3233(08)60640-3"},{"key":"1376_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132, 171\u2013183 (2008).","journal-title":"J. Control. Release"},{"key":"1376_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0735-1097(98)00311-8","volume":"32","author":"JL Cohen","year":"1998","unstructured":"Cohen, J. L. et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. J. Am. Coll. Cardiol. 32, 746\u2013752 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1376_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1376_CR40","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1172\/JCI8862","volume":"105","author":"H Birn","year":"2000","unstructured":"Birn, H. et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J. Clin. Invest. 105, 1353\u20131361 (2000).","journal-title":"J. Clin. Invest."},{"key":"1376_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/sj.ki.5000141","volume":"69","author":"H Birn","year":"2006","unstructured":"Birn, H. & Christensen, E. I. Renal albumin absorption in physiology and pathology. Kidney Int. 69, 440\u2013449 (2006).","journal-title":"Kidney Int."},{"key":"1376_CR42","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1681\/ASN.2010050492","volume":"21","author":"S Amsellem","year":"2010","unstructured":"Amsellem, S. et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J. Am. Soc. Nephrol. 21, 1859\u20131867 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1376_CR43","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","volume":"5","author":"KMK Sand","year":"2015","unstructured":"Sand, K. M. K. et al. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol. 5, 682\u2013682 (2015).","journal-title":"Front. Immunol."},{"key":"1376_CR44","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1002\/anie.201202713","volume":"51","author":"BJ Crielaard","year":"2012","unstructured":"Crielaard, B. J. et al. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew. Chem. Int. Ed. 51, 7254\u20137258 (2012).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1376_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/ar3130","volume":"12","author":"LD Quan","year":"2010","unstructured":"Quan, L. D. et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res. Ther. 12, R170 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1376_CR46","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1021\/pr500587x","volume":"13","author":"T Bennike","year":"2014","unstructured":"Bennike, T. et al. A normative study of the synovial fluid proteome from healthy porcine knee joints. J. Proteome Res. 13, 4377\u20134387 (2014).","journal-title":"J. Proteome Res."},{"key":"1376_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1947603518790009","volume":"11","author":"JD King","year":"2020","unstructured":"King, J. D. et al. Joint fluid proteome after anterior cruciate ligament rupture reflects an acute posttraumatic inflammatory and chondrodegenerative state. Cartilage 11, 329\u2013337 (2020).","journal-title":"Cartilage"},{"key":"1376_CR48","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1021\/bc500427g","volume":"25","author":"HJ Byeon","year":"2014","unstructured":"Byeon, H. J. et al. Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis. Bioconjug. Chem. 25, 2212\u20132221 (2014).","journal-title":"Bioconjug. Chem."},{"key":"1376_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1021\/mp2002522","volume":"9","author":"S Lau","year":"2012","unstructured":"Lau, S. et al. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Mol. Pharm. 9, 71\u201380 (2012).","journal-title":"Mol. Pharm."},{"key":"1376_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jconrel.2016.04.013","volume":"232","author":"K Bienk","year":"2016","unstructured":"Bienk, K. et al. An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. J. Control. Release 232, 143\u2013151 (2016).","journal-title":"J. Control. Release"},{"key":"1376_CR51","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41467-024-45609-0","volume":"15","author":"EN Hoogenboezem","year":"2024","unstructured":"Hoogenboezem, E.N. et al. Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy. Nat. Commun. 15, 1581 (2024).","journal-title":"Nat. Commun."},{"key":"1376_CR52","doi-asserted-by":"publisher","first-page":"E6490","DOI":"10.1073\/pnas.1621240114","volume":"114","author":"SM Sarett","year":"2017","unstructured":"Sarett, S. M. et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl Acad. Sci. USA 114, E6490\u2013E6497 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1376_CR53","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.joca.2017.02.797","volume":"25","author":"C Sanchez","year":"2017","unstructured":"Sanchez, C. et al. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthr. Cartil. 25, 1199\u20131209 (2017).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR54","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.joca.2012.07.021","volume":"20","author":"P Sward","year":"2012","unstructured":"Sward, P., Frobell, R., Englund, M., Roos, H. & Struglics, A. Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)\u2014a cross-sectional analysis. Osteoarthr. Cartil. 20, 1302\u20131308 (2012).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/art.1780390402","volume":"39","author":"S Nakamura","year":"1996","unstructured":"Nakamura, S. et al. Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage. Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum. 39, 539\u2013551 (1996).","journal-title":"Arthritis Rheum."},{"key":"1376_CR56","first-page":"239","volume":"51","author":"Y Nanba","year":"1997","unstructured":"Nanba, Y. et al. Expression of osteonectin in articular cartilage of osteoarthritic knees. Acta Med. Okayama 51, 239\u2013243 (1997).","journal-title":"Acta Med. Okayama"},{"key":"1376_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai, N., Trieu, V., Damascelli, B. & Soon-Shiong, P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2, 59\u201364 (2009).","journal-title":"Transl. Oncol."},{"key":"1376_CR58","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. 40, 1500\u20131508 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1376_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard-2022-222773","volume":"82","author":"AJ Knights","year":"2023","unstructured":"Knights, A. J. et al. Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis. Ann. Rheum. Dis. 82, 272\u2013282 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1376_CR60","first-page":"2203","volume":"9","author":"LR Eichaker","year":"2014","unstructured":"Eichaker, L. R., Cho, H., Duvall, C. L., Werfel, T. A. & Hasty, K. A. Future nanomedicine for the diagnosis and treatment of osteoarthritis. Nanomed. Nanotechnol. Biol. Med. 9, 2203\u20132215 (2014).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"1376_CR61","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/acsbiomaterials.6b00804","volume":"4","author":"KP O\u2019Grady","year":"2018","unstructured":"O\u2019Grady, K. P. et al. Drug-free ROS sponge polymeric microspheres reduce tissue damage from ischemic and mechanical injury. ACS Biomater. Sci. Eng. 4, 1251\u20131264 (2018).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"1376_CR62","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.nano.2015.01.011","volume":"11","author":"H Cho","year":"2015","unstructured":"Cho, H., Pinkhassik, E., David, V., Stuart, J. M. & Hasty, K. A. Detection of early cartilage damage using targeted nanosomes in a post-traumatic osteoarthritis mouse model. Nanomed. Nanotechnol. Biol. Med. 11, 939\u2013946 (2015).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"1376_CR63","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1002\/art.22875","volume":"56","author":"LG Ameye","year":"2007","unstructured":"Ameye, L. G. et al. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum. 56, 3336\u20133346 (2007).","journal-title":"Arthritis Rheum."},{"key":"1376_CR64","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.2017.5283","volume":"317","author":"TE McAlindon","year":"2017","unstructured":"McAlindon, T. E. et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967\u20131975 (2017).","journal-title":"JAMA"},{"key":"1376_CR65","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.joca.2010.05.025","volume":"18","author":"SS Glasson","year":"2010","unstructured":"Glasson, S. S., Chambers, M. G., Van Den Berg, W. B. & Little, C. B. The OARSI histopathology initiative \u2013 recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthr. Cartil. 18, S17\u2013S23 (2010).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR66","volume":"2011","author":"B Bolon","year":"2011","unstructured":"Bolon, B. et al. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J. Biomed. Biotechnol. 2011, 569068 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"1376_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","volume":"15","author":"LR Coulthard","year":"2009","unstructured":"Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F. & Burchill, S. A. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 15, 369\u2013379 (2009).","journal-title":"Trends Mol. Med."},{"key":"1376_CR68","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/JIR.S348491","volume":"15","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. p38MAPK signaling pathway in osteoarthritis: pathological and therapeutic aspects. J. Inflamm. Res. 15, 723\u2013734 (2022).","journal-title":"J. Inflamm. Res."},{"key":"1376_CR69","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.joca.2008.05.001","volume":"17","author":"SW Jones","year":"2009","unstructured":"Jones, S. W. et al. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology. Osteoarthr. Cartil. 17, 124\u2013131 (2009).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.aanat.2014.10.006","volume":"197","author":"SM Almasry","year":"2015","unstructured":"Almasry, S. M., Soliman, H. M., El-Tarhouny, S. A., Algaidi, S. A. & Ragab, E. M. Platelet rich plasma enhances the immunohistochemical expression of platelet derived growth factor and vascular endothelial growth factor in the synovium of the meniscectomized rat models of osteoarthritis. Ann. Anat. 197, 38\u201349 (2015).","journal-title":"Ann. Anat."},{"key":"1376_CR71","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bdrc.20124","volume":"84","author":"LA Solomon","year":"2008","unstructured":"Solomon, L. A., B\u00e9rub\u00e9, N. G. & Beier, F. Transcriptional regulators of chondrocyte hypertrophy. Birth Defects Res. C 84, 123\u2013130 (2008).","journal-title":"Birth Defects Res. C"},{"key":"1376_CR72","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.biocel.2007.12.005","volume":"40","author":"TL Adair-Kirk","year":"2008","unstructured":"Adair-Kirk, T. L. & Senior, R. M. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell Biol. 40, 1101\u20131110 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1376_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo, Q. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 6, 15 (2018).","journal-title":"Bone Res."},{"key":"1376_CR74","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/ard.2008.106021","volume":"69","author":"A Jungel","year":"2010","unstructured":"Jungel, A. et al. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann. Rheum. Dis. 69, 898\u2013902 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1376_CR75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/gene.2012.65","volume":"14","author":"MG Kazantseva","year":"2013","unstructured":"Kazantseva, M. G., Hung, N. A., Highton, J. & Hessian, P. A. MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. Genes Immun. 14, 162\u2013169 (2013).","journal-title":"Genes Immun."},{"key":"1376_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/ar4423","volume":"15","author":"A Singh","year":"2013","unstructured":"Singh, A. et al. Collagenase-3 (MMP-13) deficiency protects C57BL\/6 mice from antibody-induced arthritis. Arthritis Res. Ther. 15, R222 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1376_CR77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1126\/science.111.2878.204.a","volume":"111","author":"LW Granirer","year":"1950","unstructured":"Granirer, L. W. A study of the albumin and globulin content in postpartum plasma and its use in rheumatoid arthritis. Science 111, 204 (1950).","journal-title":"Science"},{"key":"1376_CR78","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/rheumatology\/keh242","volume":"43","author":"D Elewaut","year":"2004","unstructured":"Elewaut, D. Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis. Rheumatology 43, 1067\u20131068 (2004).","journal-title":"Rheumatology"},{"key":"1376_CR79","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/rheumatology\/keh254","volume":"43","author":"C Fiehn","year":"2004","unstructured":"Fiehn, C. et al. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology 43, 1097\u20131105 (2004).","journal-title":"Rheumatology"},{"key":"1376_CR80","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/ard.2007.086843","volume":"67","author":"C Fiehn","year":"2008","unstructured":"Fiehn, C., Kratz, F., Sass, G., Muller-Ladner, U. & Neumann, E. Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann. Rheum. Dis. 67, 1188\u20131191 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1376_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/03639045.2013.850705","volume":"41","author":"U Bilthariya","year":"2015","unstructured":"Bilthariya, U., Jain, N., Rajoriya, V. & Jain, A. K. Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev. Ind. Pharm. 41, 95\u2013104 (2015).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"1376_CR82","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/10495398.2021.1951282","volume":"34","author":"AM Al-Rahim","year":"2021","unstructured":"Al-Rahim, A. M. et al. Folate-methotrexate loaded bovine serum albumin nanoparticles preparation: an in vitro drug targeting cytokines overwhelming expressed immune cells from rheumatoid arthritis patients. Anim. Biotechnol. 34, 166\u2013182 (2021).","journal-title":"Anim. Biotechnol."},{"key":"1376_CR83","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1021\/acsami.0c19468","volume":"13","author":"J Lyu","year":"2021","unstructured":"Lyu, J. et al. Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils. ACS Appl. Mater. Interfaces 13, 266\u2013276 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1376_CR84","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1021\/acsnano.9b01710","volume":"13","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano 13, 5036\u20135048 (2019).","journal-title":"ACS Nano"},{"key":"1376_CR85","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/1529-0131(199805)41:5<877::AID-ART16>3.0.CO;2-#","volume":"41","author":"JL Huebner","year":"1998","unstructured":"Huebner, J. L., Otterness, I. G., Freund, E. M., Caterson, B. & Kraus, V. B. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum. 41, 877\u2013890 (1998).","journal-title":"Arthritis Rheum."},{"key":"1376_CR86","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12891-017-1913-6","volume":"18","author":"NP Thomas","year":"2017","unstructured":"Thomas, N. P. et al. Synovial inflammation plays a greater role in post-traumatic osteoarthritis compared to idiopathic osteoarthritis in the Hartley guinea pig knee. BMC Musculoskelet. Disord. 18, 556 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1376_CR87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.27765","volume":"63","author":"B Poulet","year":"2011","unstructured":"Poulet, B., Hamilton, R. W., Shefelbine, S. & Pitsillides, A. A. Characterizing a novel and adjustable noninvasive murine joint loading model. Arthritis Rheum. 63, 137\u2013147 (2011).","journal-title":"Arthritis Rheum."},{"key":"1376_CR88","unstructured":"Roehl, I., Schuster, M. & Seiffert, S. Oligonucleotide detection method. Google Patents WO2010043512A1 WIPO (PCT) (2020)."},{"key":"1376_CR89","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/nat.2017.0690","volume":"27","author":"B Godinho","year":"2017","unstructured":"Godinho, B. et al. Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay. Nucleic Acid Ther. 27, 323\u2013334 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"1376_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.joca.2014.09.019","volume":"23","author":"A Kumar","year":"2015","unstructured":"Kumar, A., Bendele, A. M., Blanks, R. C. & Bodick, N. Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis. Osteoarthr. Cartil. 23, 151\u2013160 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"1376_CR91","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1096\/fj.09-129874","volume":"23","author":"HF Zhou","year":"2009","unstructured":"Zhou, H. F., Chan, H. W., Wickline, S. A., Lanza, G. M. & Pham, C. T. \u03b1v\u03b23-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 23, 2978\u20132985 (2009).","journal-title":"FASEB J."},{"key":"1376_CR92","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00292-006-0864-8","volume":"27","author":"T Aigner","year":"2006","unstructured":"Aigner, T. & S\u00f6der, S. Histopathologische Begutachtung der Gelenkdegeneration. Pathologe 27, 431\u2013438 (2006).","journal-title":"Pathologe"},{"key":"1376_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj1414","volume":"7","author":"YR Choi","year":"2021","unstructured":"Choi, Y. R. et al. A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery. Sci. Adv. 7, eabj1414 (2021).","journal-title":"Sci. Adv."},{"key":"1376_CR94","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1007\/BF01778296","volume":"44","author":"PA Jimenez","year":"1995","unstructured":"Jimenez, P. A., Harlan, P. M., Chavarria, A. E. & Haimes, H. B. Induction of osteoarthritis in guinea pigs by transection of the anterior cruciate ligament: radiographic and histopathological changes. Inflamm. Res. 44, S129\u2013S130 (1995).","journal-title":"Inflamm. Res."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01376-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:39:11Z","timestamp":1757173151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":94,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01376-x","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}